# Absci Corp: financial statements, quarterly

ABSI · Nasdaq · CIK 1672688 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/absi.md) · [Financials](/companies/absi/financials.md) · [Filings](/companies/absi/filings.md) · [Insiders](/companies/absi/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/absi/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.7](/filings/0001628280-24-046862.md) | [0.3 d](/filings/0001628280-25-013464.md) | [0.9](/filings/0001628280-24-023062.md) | [1.3](/filings/0001628280-24-037193.md) | [1.7](/filings/0001628280-24-046862.md) | [0.7 d](/filings/0001628280-25-013464.md) | [1.2](/filings/0001672688-26-000088.md) | [0.6](/filings/0001672688-26-000136.md) | [0.4](/filings/0001672688-25-000084.md) | [0.7 d](/filings/0001672688-26-000068.md) | [0.2](/filings/0001672688-26-000088.md) | [0.3](/filings/0001672688-26-000136.md) |
| Research and development | $m | [11.0](/filings/0001628280-24-046862.md) | [12.3 d](/filings/0001628280-25-013464.md) | [12.2](/filings/0001628280-25-025077.md) | [15.3](/filings/0001628280-25-039938.md) | [18.0](/filings/0001672688-25-000084.md) | [18.4 d](/filings/0001672688-26-000068.md) | [16.4](/filings/0001672688-26-000088.md) | [20.5](/filings/0001672688-26-000136.md) | [19.2](/filings/0001672688-25-000084.md) | [25.3 d](/filings/0001672688-26-000068.md) | [19.3](/filings/0001672688-26-000088.md) | [22.6](/filings/0001672688-26-000136.md) |
| Selling, general and administrative | $m | [9.5](/filings/0001628280-24-046862.md) | [9.3 d](/filings/0001628280-25-013464.md) | [8.7](/filings/0001628280-25-025077.md) | [9.3](/filings/0001628280-25-039938.md) | [9.3](/filings/0001672688-25-000084.md) | [8.8 d](/filings/0001672688-26-000068.md) | [9.5](/filings/0001672688-26-000088.md) | [8.5](/filings/0001672688-26-000136.md) | [8.4](/filings/0001672688-25-000084.md) | [8.6 d](/filings/0001672688-26-000068.md) | [9.1](/filings/0001672688-26-000088.md) | [9.2](/filings/0001672688-26-000136.md) |
| Operating income | $m | [(23.3)](/filings/0001628280-24-046862.md) | [(24.7) d](/filings/0001628280-25-013464.md) | [(23.5)](/filings/0001628280-25-025077.md) | [(26.7)](/filings/0001628280-25-039938.md) | [(28.9)](/filings/0001672688-25-000084.md) | [(29.8) d](/filings/0001672688-26-000068.md) | [(27.7)](/filings/0001672688-26-000088.md) | [(31.4)](/filings/0001672688-26-000136.md) | [(30.2)](/filings/0001672688-25-000084.md) | [(31.0) d](/filings/0001672688-26-000068.md) | [(30.8)](/filings/0001672688-26-000088.md) | [(34.2)](/filings/0001672688-26-000136.md) |
| Interest expense | $m | [0.2](/filings/0001628280-23-038983.md) | [0.2 d](/filings/0001628280-24-012366.md) | [0.2](/filings/0001628280-24-023062.md) | [0.2](/filings/0001628280-25-039938.md) | [0.1](/filings/0001672688-25-000084.md) | [0.1 d](/filings/0001672688-26-000068.md) | [0.1](/filings/0001672688-26-000088.md) | [0.1](/filings/0001672688-26-000136.md) | [0.0](/filings/0001672688-25-000084.md) | [0.0 d](/filings/0001672688-26-000068.md) | [0.0](/filings/0001672688-26-000088.md) | [0.0](/filings/0001672688-26-000136.md) |
| Income tax | $m | [0.0](/filings/0001628280-24-046862.md) | [0.0 d](/filings/0001628280-25-013464.md) | [0.0](/filings/0001628280-25-025077.md) | [0.0](/filings/0001628280-25-039938.md) | [0.0](/filings/0001672688-25-000084.md) | [0.0 d](/filings/0001672688-26-000068.md) | [(0.0)](/filings/0001672688-26-000088.md) | [0.1](/filings/0001672688-26-000136.md) | [0.1](/filings/0001672688-25-000084.md) | [(0.2) d](/filings/0001672688-26-000068.md) | [0.0](/filings/0001672688-26-000088.md) | [0.0](/filings/0001672688-26-000136.md) |
| Net income | $m | [(22.0)](/filings/0001628280-24-046862.md) | [(23.5) d](/filings/0001628280-25-013464.md) | [(22.0)](/filings/0001672688-25-000084.md) | [(24.8)](/filings/0001672688-25-000084.md) | [(27.4)](/filings/0001672688-25-000084.md) | [(29.0) d](/filings/0001672688-26-000068.md) | [(26.3)](/filings/0001672688-26-000136.md) | [(30.6)](/filings/0001672688-26-000136.md) | [(28.7)](/filings/0001672688-25-000084.md) | [(29.6) d](/filings/0001672688-26-000068.md) | [(29.6)](/filings/0001672688-26-000136.md) | [(33.2)](/filings/0001672688-26-000136.md) |
| Diluted EPS | $ per share | [(0.24)](/filings/0001628280-24-046862.md) | not reported | [(0.22)](/filings/0001628280-25-025077.md) | [(0.22)](/filings/0001628280-25-039938.md) | [(0.24)](/filings/0001672688-25-000084.md) | not reported | [(0.21)](/filings/0001672688-26-000088.md) | [(0.24)](/filings/0001672688-26-000136.md) | [(0.20)](/filings/0001672688-25-000084.md) | not reported | [(0.19)](/filings/0001672688-26-000088.md) | [(0.21)](/filings/0001672688-26-000136.md) |
| Basic EPS | $ per share | [(0.24)](/filings/0001628280-24-046862.md) | not reported | [(0.22)](/filings/0001628280-25-025077.md) | [(0.22)](/filings/0001628280-25-039938.md) | [(0.24)](/filings/0001672688-25-000084.md) | not reported | [(0.21)](/filings/0001672688-26-000088.md) | [(0.24)](/filings/0001672688-26-000136.md) | [(0.20)](/filings/0001672688-25-000084.md) | not reported | [(0.19)](/filings/0001672688-26-000088.md) | [(0.21)](/filings/0001672688-26-000136.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [69.7](/filings/0001628280-23-038983.md) | [72.4](/filings/0001628280-25-013464.md) | [58.8](/filings/0001628280-24-023062.md) | [42.9](/filings/0001628280-24-037193.md) | [38.2](/filings/0001628280-24-046862.md) | [41.2](/filings/0001672688-26-000068.md) | [47.0](/filings/0001628280-25-025077.md) | [38.0](/filings/0001628280-25-039938.md) | [9.5](/filings/0001672688-25-000084.md) | [20.0](/filings/0001672688-26-000136.md) | [8.6](/filings/0001672688-26-000088.md) | [108](/filings/0001672688-26-000136.md) |
| Current assets | $m | [135](/filings/0001628280-23-038983.md) | [121](/filings/0001628280-25-013464.md) | [182](/filings/0001628280-24-023062.md) | [165](/filings/0001628280-24-037193.md) | [150](/filings/0001628280-24-046862.md) | [134](/filings/0001672688-26-000068.md) | [156](/filings/0001628280-25-025077.md) | [137](/filings/0001628280-25-039938.md) | [175](/filings/0001672688-25-000084.md) | [150](/filings/0001672688-26-000136.md) | [132](/filings/0001672688-26-000088.md) | [208](/filings/0001672688-26-000136.md) |
| Total assets | $m | [236](/filings/0001628280-23-038983.md) | [217](/filings/0001628280-25-013464.md) | [275](/filings/0001628280-24-023062.md) | [256](/filings/0001628280-24-037193.md) | [235](/filings/0001628280-24-046862.md) | [214](/filings/0001672688-26-000068.md) | [232](/filings/0001628280-25-025077.md) | [210](/filings/0001628280-25-039938.md) | [245](/filings/0001672688-25-000084.md) | [216](/filings/0001672688-26-000136.md) | [196](/filings/0001672688-26-000088.md) | [269](/filings/0001672688-26-000136.md) |
| Current liabilities | $m | [28.0](/filings/0001628280-23-038983.md) | [29.6](/filings/0001628280-25-013464.md) | [25.3](/filings/0001628280-24-023062.md) | [25.5](/filings/0001628280-24-037193.md) | [26.7](/filings/0001628280-24-046862.md) | [28.7](/filings/0001672688-26-000068.md) | [27.3](/filings/0001628280-25-025077.md) | [31.3](/filings/0001628280-25-039938.md) | [29.7](/filings/0001672688-25-000084.md) | [22.8](/filings/0001672688-26-000136.md) | [20.0](/filings/0001672688-26-000088.md) | [19.6](/filings/0001672688-26-000136.md) |
| Total liabilities | $m | [39.9](/filings/0001628280-23-038983.md) | [41.1](/filings/0001628280-25-013464.md) | [34.8](/filings/0001628280-24-023062.md) | [34.0](/filings/0001628280-24-037193.md) | [33.9](/filings/0001628280-24-046862.md) | [34.5](/filings/0001672688-26-000068.md) | [33.7](/filings/0001628280-25-025077.md) | [36.5](/filings/0001628280-25-039938.md) | [34.7](/filings/0001672688-25-000084.md) | [26.8](/filings/0001672688-26-000136.md) | [23.6](/filings/0001672688-26-000088.md) | [22.8](/filings/0001672688-26-000136.md) |
| Long-term debt | $m | not reported | [7.9](/filings/0001628280-24-012366.md) | not reported | not reported | not reported | [4.0](/filings/0001628280-25-013464.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [196](/filings/0001628280-24-046862.md) | [176](/filings/0001672688-26-000068.md) | [240](/filings/0001672688-25-000084.md) | [221](/filings/0001672688-25-000084.md) | [201](/filings/0001672688-25-000084.md) | [179](/filings/0001672688-26-000136.md) | [199](/filings/0001672688-26-000136.md) | [173](/filings/0001672688-26-000136.md) | [210](/filings/0001672688-25-000084.md) | [189](/filings/0001672688-26-000136.md) | [172](/filings/0001672688-26-000136.md) | [246](/filings/0001672688-26-000136.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.4) d](/filings/0001628280-24-046862.md) | [(14.9) d](/filings/0001628280-25-013464.md) | [(17.9)](/filings/0001628280-25-025077.md) | [(16.8) d](/filings/0001628280-25-039938.md) | [(20.7) d](/filings/0001672688-25-000084.md) | [(17.0) d](/filings/0001672688-26-000068.md) | [(21.8)](/filings/0001672688-26-000088.md) | [(16.9) d](/filings/0001672688-26-000136.md) | [(25.0) d](/filings/0001672688-25-000084.md) | [(29.2) d](/filings/0001672688-26-000068.md) | [(26.3)](/filings/0001672688-26-000088.md) | [(27.6) d](/filings/0001672688-26-000136.md) |
| Capital expenditure | $m | [0.3 d](/filings/0001628280-24-046862.md) | [0.0 d](/filings/0001628280-25-013464.md) | [0.0](/filings/0001628280-25-025077.md) | [0.3 d](/filings/0001628280-25-039938.md) | [0.0 d](/filings/0001672688-25-000084.md) | [0.0 d](/filings/0001672688-26-000068.md) | [0.0](/filings/0001672688-26-000088.md) | [0.2 d](/filings/0001672688-26-000136.md) | [1.0 d](/filings/0001672688-25-000084.md) | [(0.1) d](/filings/0001672688-26-000068.md) | [0.0](/filings/0001672688-26-000088.md) | [0.0 d](/filings/0001672688-26-000136.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [91.1](/filings/0001628280-23-038983.md) | [91.5](/filings/0001628280-24-023062.md) | [91.8](/filings/0001628280-24-037193.md) | [92.2](/filings/0001628280-24-046862.md) | [99.4](/filings/0001628280-25-025077.md) | [113](/filings/0001628280-25-039938.md) | [114](/filings/0001672688-25-000084.md) | [124](/filings/0001672688-26-000088.md) | [128](/filings/0001672688-26-000136.md) | [144](/filings/0001672688-25-000084.md) | [153](/filings/0001672688-26-000088.md) | [157](/filings/0001672688-26-000136.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 171,614,010 at 2026-07-31, from the cover of the [10-Q filed 2026-08-11](/filings/0001672688-26-000136.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.